Tumours producing big IGF-II overwhelm the processing enzymes, leading to its accumulation and subsequent insulin-like effects, causing recurrent and severe hypoglycaemia through multiple mechanisms which include increased peripheral glucose uptake, reduced lipolysis, reduced free fatty acids, reduced hepatic gluconeogenesis, reduced glycogenolysis, and decreased growth hormone secretion from anterior pituitary [16]. Here, IGF2 is linked to neoplasm.